A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf
.
Therapeutic Effect of Repurposed Temsirolimus in Lung Adenocarcinoma Model
2018
Frontiers in Pharmacology
Lung cancer is one of the major cause of cancer-related deaths worldwide. The poor prognosis and resistance to both radiation and chemotherapy urged the development of potential targets for lung cancer treatment. In this study, using a network-based cellular signature bioinformatics approach, we repurposed a clinically approved mTOR inhibitor for renal cell carcinomans, temsirolimus, as the potential therapeutic candidate for lung adenocarcinoma. The PI3K-AKT-mTOR pathway is known as one of the
doi:10.3389/fphar.2018.00778
pmid:30087612
pmcid:PMC6066584
fatcat:vf2srikjnfbd7mzldvbytkbaje